The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is well established that tumors are dependent on angiogenesis for their growth and survival. Although uterine fibroids are known to be benign tumors with reduced vascularization, recent work demonstrates that the vasculature of fibroids is grossly and microscopically abnormal. Accumulating evidence suggests that angiogenic growth factor dysregulation may be implicated in these vascular and other features of fibroid pathophysiology. METHODS: Literature searches were performed in PubMed and Google Scholar for articles with content related to angiogenic growth factors and myometrium/leiomyoma. The findings are hereby reviewed and discussed. RESULTS: Multiple growth factors involved in angiogenesis are differentially expressed in leiomyoma compared with myometrium. These include epidermal growth factor (EGF), heparin-binding-EGF, vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor, transforming growth factor-β and adrenomedullin. An important paradox is that although leiomyoma tissues are hypoxic, leiomyoma feature down-regulation of key molecular regulators of the hypoxia response. Furthermore, the hypoxic milieu of leiomyoma may contribute to fibroid development and growth. Notably, common treatments for fibroids such as GnRH agonists and uterine artery embolization (UAE) are shown to work at least partly via anti-angiogenic mechanisms. CONCLUSIONS: Angiogenic growth factors play an important role in mechanisms of fibroid pathophysiology, including abnormal vasculature and fibroid growth and survival. Moreover, the fibroid's abnormal vasculature together with its aberrant hypoxic and angiogenic response may make it especially vulnerable to disruption of its vascular supply, a feature which could be exploited for treatment. Further experimental studies are required in order to gain a better understanding of the growth factors that are involved in normal and pathological myometrial angiogenesis, and to assess the potential of anti-angiogenic treatment strategies for uterine fibroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“…glucose transporter-1 and enhanced glycolysis by up-regulation of key glycolytic enzymes such as carbonic anhydrase IX, increased angiogenesis by overexpression of VEGF and activation of the c-MET/HGF system characterized by cell proliferation, migration and apoptosis protection (Semenza, 2003).”
BackgroundRisau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727 · cited 2×
“Elongation occurs in growing tissues as existing vessels constantly restructure in response to the metabolic demands of the surrounding cells, a process also known as remodeling or pruning (Risau, 1997; Fig.”
BackgroundJaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“…an abnormal hypoxia response of fibroids: implications for growth and vascularization Tumor hypoxia is a crucial driving force in malignant progression promoting local invasion, intravasation and metastatic spread, and has been shown to correlate closely with poor patient prognosis (Harris, 2002).”
BackgroundEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 2×
“To date, the expression of other angiogenesis inhibitors such as angiopoietin-2 (Maisonpierre et al., 1997), angiostatin (O’Reilly et al., 1994) and endostatin (O’Reilly et al., 1997) has not been investigated in fibroids and would be an interesting avenue to explore.”
BackgroundKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 2×
“Some are angiogenic growth factor inhibitors such as the antiVEGF monoclonal antibody, bevacizumab (Ferrara et al., 2004), which is FDA-approved for treatment of metastatic colon cancer; some are endogenous angiogenesis inhibitors, proteins or fragments of proteins formed in the body that inhibit…”
BackgroundA conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 4×
“Consistent with this hypothesis, it was shown that HIF-1a disruption prevents the formation of large blood vessels and impairs vascular function, resulting in a hypoxic microenvironment within the tumor mass (Carmeliet et al., 1998).”
BackgroundInfluentialRAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134 · cited 1×
“CLR association with RAMP2 or RAMP3 promotes adrenomedullin binding, whereas heterodimerization with RAMP1 promotes CGRP binding (McLatchie et al., 1998).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676 · cited 1×
“The TSC1/TSC2 complex functions as a GTPase activator for the RAS homologue enriched in the brain (Rheb), promoting Rheb inactivation (Pouyssegur et al., 2006).”
BackgroundThe Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635 · cited 1×
“HLRCC results from an inactivating germline mutation in the fumarate hydratase (FH) gene, which encodes the Krebs cycle enzyme which acts as a classical tumor suppressor (Tomlinson et al., 2002; Alam et al., 2003).”
BackgroundAsparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 1×
“…hydroxylation at residue N803 within the C-transactivation domain of HIF-1a by the action of the asparaginyl hydroxylase factor-inhibiting HIF-1 inhibits the interaction of HIF-1a with various co-activators such as p300/CBP, resulting in its inactivation (Mahon et al., 2001; Lando et al., 2002).”
BackgroundMahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 2×
“, 2006) or regulated in development and DNA damage response (REDD1; Brugarolas et al., 2004).”
BackgroundFolkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF
Higashiyama, S., Abraham, J. A., Miller, J., Fiddes, J. C., & Klagsbrun, M. (1991) · Science · doi:10.1126/science.1840698 · Cited by 1,127 · cited 7×
“HB-EGF is a potent autocrine/paracrine mitogen for fibroblasts, SMCs, keratinocytes and endometrial stromal cells (Higashiyama et al., 1991; Marikovsky et al., 1993; Chobotova et al., 2002), as well as a chemo-attractant for SMCs (Higashiyama et al.”
BackgroundInfluentialMasson, N., Willam, C., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.18.5197 · Cited by 1,014 · cited 1×
“…between the tumor suppressor Von-Hippel– Lindau (VHL) and HIF-1a is enabled by two prolyl hydroxylations within the HIF-1a degradation domain, at residues P402 and P564 by prolyl hydroxylases (PHDs; Bruick and McKnight, 2001; Epstein et al., 2001; Jaakkola et al., 2001; Masson et al., 2001).”
BackgroundIsaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958 · cited 1×
“…FH activity has been shown to result in accumulation of fumarate leading to inhibition of HIF prolyl hydroxylase and consequent HIF-1a stabilization and activation, with a subsequent release of hypoxia-inducible factors such as VEGF (Isaacs et al., 2005; Pollard et al., 2005b; Selaket al., 2005).”
BackgroundPollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865
Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation.
Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M., & Massague, J. (1990) · Cell · doi:10.1016/0092-8674(90)90251-9 · Cited by 797
Inherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669 · cited 1×
“In addition, rare genetic conditions such as hereditary leiomyomatosis and renal cell cancer (HLRCC) and Alport syndrome development of feature leiomyoma (Launonen et al., 2001;Ulianaetal., 2011).”
BackgroundAdam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585 · cited 1×
“Moreover, renal cyst formation occurs in FH-deficient mice but not in PHD-deficient mice despite identical HIF-1a overexpression (Adam et al., 2011), suggesting that additional mechanisms independent of HIF-1a are required for malignant transformation.”
BackgroundEndogenous inhibitors of angiogenesis
Ribatti, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.019 · Cited by 191 · cited 2×
“…proteins or fragments of proteins formed in the body that inhibit the formation of new blood vessels, such as angiostatin and endostatin (Ribatti, 2009); some are analogues of fumagillin (i.e. TNP-470), a naturally occurring antibiotic with antiangiogenic activity (Ingber et al., 1990);…”
BackgroundRole of stem cells in human uterine leiomyoma growth
Ono, M., Qiang, W., Serna, V. A., Yin, P., Coon, J. S., Navarro, A., Monsivais, D., Kakinuma, T., Dyson, M., Druschitz, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036935 · Cited by 141 · cited 2×
“Upon implantation into immunodeficient mice, these myometrial stem cells were shown to form large leiomyoma tumors with higher proliferative activity than regular myometrial cells which formed much smaller tumors (Ono et al., 2012), suggesting that myometrial stem cellsmaybe critical for leiomyomadevelopment.”
BackgroundPollard, P., Wortham, N., Barclay, E., Alam, A., Elia, G., Manek, S., Poulsom, R., & Tomlinson, I. (2005) · The Journal of Pathology · doi:10.1002/path.1686 · Cited by 100
Bardella, C., Olivero, M., Lorenzato, A., Geuna, M., Adam, J., O'Flaherty, L., Rustin, P., Tomlinson, I., Pollard, P. J., & Di Renzo, M. F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06160-11 · Cited by 33
Metadata
- Authors
- Tal, R., & Segars, J. H.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-29
- Volume
- 20
- Issue
- 2
- Pages
- 194-216
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2134685322
- Cited by
- 159
- References
- 32
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.